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The effects of hydrocortisone on systemic arterial blood pressure
and urinary protein excretion in dogs
Abstract
BACKGROUND: Hypertension and proteinuria are commonly recognized in dogs with spontaneous
hypercortisolism. There is, however, little information regarding the effect of exogenous glucocorticoids
on blood pressure (BP) and proteinuria and whether these changes are reversible. HYPOTHESIS:
Hydrocortisone administration increases systemic BP and urinary protein excretion, and these effects are
reversible after hydrocortisone withdrawal. Animals: Six control dogs and 6 dogs treated with
hydrocortisone. METHODS: BP, urine protein : creatinine ratio (UPC), microalbuminuria (MALB),
urine albumin : creatinine ratio (UAC), and urine gel electrophoresis were evaluated before, during, and
after administration of hydrocortisone (8 mg/kg PO q12h for 12 weeks) or placebo. RESULTS: BP and
UPC increased substantially during hydrocortisone administration from 123 mmHg (range 114-136
mmHg) and 0.17 (0.15-0.28) to a maximum of 143 mmHg (128-148 mmHg) and 0.38 (0.18-1.78),
respectively, on day 28. MALB developed in 4 dogs and UAC significantly increased in all dogs during
hydrocortisone administration with the maximum on day 84. Both increases in BP and proteinuria were
reversible and completely resolved within 1 month after stopping hydrocortisone administration.
SDS-AGE revealed the proteinuria to be primarily albuminuria with a pronounced increase during
hydrocortisone treatment. Furthermore, a protein of 25-30 kDa was found in male dogs, identified by
mass spectrometry to be arginine esterase, the major secretory prostatic protein. CONCLUSIONS AND
CLINICAL IMPORTANCE: Long-term hydrocortisone treatment results in significant but only mild
increases in systemic BP and urinary protein excretion, which are both reversible within 1 month after
discontinuation of hydrocortisone.
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ABSTRACT 24 
Background: Hypertension and proteinuria are commonly recognized in dogs with spontaneous 25 
hypercortisolism. There is, however, little information regarding the effect of exogenous 26 
glucocorticoids on blood pressure (BP) and proteinuria and whether these changes are reversible. 27 
Hypothesis: Hydrocortisone administration increases systemic BP and urinary protein excretion, 28 
and these effects are reversible after hydrocortisone withdrawal. 29 
Animals: 6 control dogs and 6 dogs treated with hydrocortisone. 30 
Methods: BP, urine protein:creatinine ratio (UPC), microalbuminuria (MALB), urine 31 
albumin:creatinine ratio (UAC) and urine gel electrophoresis were evaluated before, during and 32 
after administration of hydrocortisone (8mg/kg p.o. q12h for 12 weeks) or placebo.  33 
Results: BP and UPC increased significantly during hydrocortisone administration from 123 34 
mmHg (range 114-136 mmHg) and 0.17 (0.15-0.28) to a maximum of 143 mmHg (128-148 35 
mmHg) and 0.38 (0.18-1.78), respectively on day 28. MALB developed in four dogs and UAC 36 
significantly increased in all dogs during hydrocortisone administration with the maximum on 37 
day 84 (0.133 (0.034-1.251)). Both, BP elevation and proteinuria were reversible and completely 38 
resolved within one month after stopping hydrocortisone administration. SDS-AGE revealed the 39 
proteinuria to be primarily albuminuria with a pronounced increase during hydrocortisone 40 
treatment. Furthermore, a protein of 25-30 kDa was found in male dogs, identified by mass 41 
spectrometry to be arginine esterase, the major secretory prostatic protein.  42 
Conclusions and Clinical Importance: Long-term hydrocortisone treatment results in significant 43 
but only mild increases in systemic BP and urinary protein excretion, which are both reversible 44 
within one month after discontinuation of hydrocortisone.  45 
Key words: Hypercortisolism, Hypertension, Proteinuria, Albuminuria, Arginine Esterase 46 
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INTRODUCTION 47 
Hypertension is a frequent finding in humans and dogs with exogenous or endogenous 48 
glucocorticoid excess. The prevalence of systemic hypertension in human patients with 49 
spontaneous (endogenous) hypercortisolism (HC) has been reported to be approximately 80%.1 50 
In experimental studies in humans, glucocorticoids have been shown to increase systolic (SAP) 51 
as well as diastolic (DAP) arterial blood pressure.2,3 Significant increases in SAP were identified 52 
within 24 hours of cortisol administration, but iatrogenic glucocorticoid-induced hypertension 53 
appears to be less severe than in the natural disease.2 The prevalence of hypertension in dogs 54 
with spontaneous HC is similar at 59-86%.4,5 When treating dogs with spontaneous HC, 55 
adequate suppression of cortisol secretion results in decreasing blood pressure (BP), however, 56 
hypertension is still common in the population of well controlled HC.4 In contrast, in 57 
experimental dogs treated with hydrocortisone for several weeks, SAP was not significantly 58 
higher compared to placebo treated dogs.6 59 
Proteinuria is also commonly observed in dogs with HC. The incidence of pathological 60 
proteinuria, defined as a urine protein:creatinine ratio (UPC) greater than 1.0, has been reported 61 
to be 44 - 75%.4,7 Experimentally, longterm administration of prednisolone resulted in 62 
proteinuria of glomerular origin.8 The reversibility of proteinuria in spontaneous HC is 63 
controversial. Whereas Ortega et al. found a significant decrease in UPC in dogs with well-64 
controlled HC, Hurley and Vaden did not.4,7 65 
Much of the existing information about the effects of glucocorticoids on blood pressure and 66 
proteinuria has been generated by experimental studies that used prednisolone for the induction 67 
of proteinuria and hypertension. However, in spontaneous HC the endogenous glucocorticoid 68 
hydrocortisone seems to be the major cause of clinical and laboratory abnormalities.9 69 
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In view of the paucity of knowledge on the effect of hydrocortisone on systemic BP, urinary 70 
protein excretion, and particularly the reversibility of such changes in dogs, the purpose of this 71 
study was to induce experimental HC using hydrocortisone as an attempt to most closely mimic 72 
the natural disease. The specific goals then were first to assess the developement and severity of 73 
hypertension, second quantitating and characterizing the glucocorticoid induced proteinuria, 74 
third to assess the association between urinary protein excretion and BP, and fourth, to study the 75 
reversibility of these changes.  76 
 77 
MATERIAL AND METHODS 78 
This randomized, placebo-controlled study was approved by the Cantonal Veterinary Office 79 
(Zurich, Canton of Zurich, Switzerland). 80 
Dogs 81 
The study was conducted using twelve 3.5-year old Beagle dogs, 6 intact males and 6 intact 82 
females, with a body weight ranging from 10.4 to 16.6 kg (median 12.9 kg). The dogs were 83 
determined to be healthy on the basis of physical examination, CBC, serum biochemistry profile, 84 
urinalysis, urine culture, UPC ratio and indirect BP measurement.  85 
Study Design 86 
HC was induced by hydrocortisone, the synthetic glucocorticoid most similar to cortisol. The 87 
dosage was chosen extrapolating from previous studies inducing I-HC  in dogs.6,8 Dogs were 88 
randomly allocated to two groups of 6 dogs. Dogs in the control group received a placebo gelatin 89 
capsule PO q12h while dogs in the treatment group received hydrocortisonea at a median dose of 90 
8.5 mg/kg (range of 7.5-9.6 mg/kg) PO q 12h for 84 days (I-HC group). Dogs were examined 91 
before (d0), and 1 (d1), 5 (d5), 28 (d28), 56 (d56), 84 (d84) days after starting treatment and 1 92 
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(d1p), 5 (d5p), 28 (d28p), 56 (d56p) and 84 (d84p) days after withdrawal of hydrocortisone and 93 
placebo, respectively. Dogs were observed for typical cortisol-induced clinical abnormalities 94 
including PU/PD and hair loss , but only subjectively, i.e. water intake and urine production were 95 
not quantitated and it was not attempted to use a scoring system for the skin abnormalities. On 96 
d0, d28, d56, d84, and d1p an ACTH stimulation test was performed in all dogs by obtaining 97 
samples for determination of cortisol before and 1 hour after IM injection of 0.25 mg of synthetic 98 
ACTHb. Cortisol concentrations were determined by use of a previously validated 99 
chemiluminescence method (ADVIA Centaur® System, Bayer (Schweiz) AG, Zurich, 100 
Switzerland).10 101 
Blood pressure measurement 102 
Before the beginning of the study, dogs were acclimated to the blood pressure measurement 103 
procedure on 12 different days, to minimize excitement and anxiety during the study.c Systolic 104 
(SAP), diastolic (DAP) and mean (MAP) arterial pressure were measured using an indirect 105 
oscillometric deviced. An inflatable cuff of approximately 40% of the tail circumference was 106 
placed directly around the base of the tail without clipping hair.11 Before recording BP, dogs 107 
were placed in left lateral recumbency and allowed to acclimate to the surroundings for at least 108 
10 minutes and the first BP readings were discarded. For data analysis the arithmetic mean of 10 109 
measurements was used.  110 
Urinary Samples  111 
Urine samples were collected from each dog by use of ultrasound-guided cystocentesis for 112 
routine urinalysis, urine culture, UPC, and for assessing microalbuminuria, urine 113 
albumin:creatinine ratio (UAC) and urine protein electrophoresis.  114 
Assessment of proteinuria 115 
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Urine protein:creatinine ratio 116 
Total urine protein levels were assayed on an autoanalyzer by an immunoturbidimetric method. 117 
Urine creatinine concentrations were determined using a commercial autoanalyzer-based kinetic 118 
Jaffe reaction and UPC ratios were calculated. 119 
Microalbuminuria and urine albumin:creatinine ratio 120 
Urine albumin concentration was determined by two different methods. Microalbuminuria 121 
(MALB) was assayed semiquantitatively by means of the canine E.R.D.-Health Screen teste  122 
after urine samples were normalized to a urine-specific gravity of 1.010 to allow comparison 123 
among samples. The amount is indicated as none (negative), small (+), moderate (++), and high 124 
(+++). To quantitate albuminuria, a modified human immunoturbidimetric assayf validated for 125 
the dog was used as described previously12, and UAC ratios were calculated. To assess 126 
sensitivity and specificity of the MALB, 2 different UAC cut-offs were chosen, first the 127 
mean+2SD obtained in our control dogs, second 0.03, the cut-off for pathologic 128 
microalbuminuria in people.13 129 
Urine protein electrophoresis 130 
Urinary proteins were separated by sodium dodecyl sulfate agarose gel electropheresis (SDS-131 
AGE) using the Hydragel proteinurie kitg.14 Briefly, twenty microliters of a 10 g/L SDS solution 132 
were added to 80 μL of urine. Five microliters were loaded to each well (5 wells/gel) and 133 
submitted to electrophoresis in an SDS-imidazole pH 7.0 buffer. After the gel was completely 134 
dried at 80 °C for 20 min, it was immersed for 30 min in an aqueous staining solution (acid 135 
violet) and destained in two successive aqueous baths before it was immersed in a glycerol 136 
aqueous solution and dried at 80°C (15 min). 137 
Characterization of the male specific protein 138 
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Gel protein bands were cut with a scalpel and repeatedly washed in 25 mM NH4HCO3 with 139 
subsequent shrinking of the gel pieces through addition of 50 % acetonitrile in 25 mM 140 
NH4HCO3. The proteins were digested overnight by adding 19 ng/µl sequencing grade modified 141 
trypsinh in 47mM Tris pH 9. Peptides were extracted from the gel by sonification in buffer A (2 142 
% acetonitrile, 0.1 % trifluoroacetic acid). For liquid chromatography electrospray ionisation 143 
tandem mass spectrometry (LC-ESI-MS/MS) analysis the protein supernatant was run over a 144 
C18 column eluting the peptides at 600 nl/min in 45 min by using a gradient of 95 % buffer A to 145 
60 % buffer B (80 % acetonitrile, 0.1 % trifluoroacetic acid). Peptides were ionized using electro 146 
spray ionization and directly injected into the massspectrometer LCQ Deca XPi recording their 147 
mass-to-charge ratio. Following each full MS spectrum the two most intense peaks were 148 
automatically selected for fragmentation of these peptides and recording of the MSMS signals 149 
(fragments). All MSMS spectra were submitted to Mascot15 for identification of the proteins. 150 
Statistical analysis 151 
Results were analyzed by use of nonparametric statistical methodsj,k, and reported as median and 152 
ranges. Differences within one group were tested by use of Friedman's repeated measures test 153 
followed by Dunn's post-tests. Differences between the groups were tested by use of the Mann-154 
Whitney U test. Differences were considered significant at values of p ≤ 0.05.  155 
 156 
RESULTS 157 
Induction of HC 158 
In this model, long-term hydrocortisone administration effectively created hypercortisolism. All 159 
dogs receiving hydrocortisone developed clinical signs (polyuria, polydipsia, no regrowth of 160 
clipped hair within one month, and thinning of the ventral abdominal skin with prominent 161 
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subcutaneous veins), and laboratory abnormalities (stress leukogram, increased alkaline 162 
phosphatase activity, isosthenuria) consistent with cortisol excess. During medication dogs in the 163 
I-HC group had significantly higher baseline plasma cortisol concentrations than dogs in the 164 
control group (e.g. d56: 3 hours post pill 30.7 mcg/dl (13.3-57.6) versus 0.5 mcg/dl (0.1-2.5)). 165 
Finally, 36 hours after hydrocortisone withdrawal dogs in the I-HC group failed to respond to 166 
ACTH stimulation; median plasma cortisol concentrations before and after ACTH administration 167 
were 0.25 mcg/dl (0.1 – 1.4 mcg/dl) and 0.45 mcg/dl (0.1 - 2 mcg/dl), respectively.  168 
Blood pressure 169 
Initially, median SAP, DAP and MAP were 128 mmHg (122 - 142 mmHg), 63 mmHg (55 - 83 170 
mmHg), and 90 mmHg (78 - 104 mmHg) in the control group and 123 mmHg (114 - 136 171 
mmHg), 69 mmHg (53 - 78 mmHg), and 90 mmHg (81 - 101 mmHg) in the I-HC group, 172 
respectively. Hydrocortisone but not placebo treatment resulted in a progressively increasing 173 
SAP, DAP and MAP that peaked on day 28 (Table 1). The increase in SAP above baseline was 174 
significant on day 28 (p < 0.01) and 56 (p < 0.05), but not anymore on d84. Elevations of DAP 175 
and MAP were significant on d28, d56 and d84. SAP, DAP and MAP decreased to baseline 176 
values within the first 5 days after hydrocortisone withdrawal, and did not change over the 177 
following 11 weeks (Table 1).  178 
Proteinuria  179 
Urine protein:creatinine ratio 180 
Initially, UPC was below 0.4 in all dogs (0.17; 0.13-0.38). No change in UPC was seen in 181 
control dogs throughout the study (Table 2). In the I-HC group, UPC ratios increased 182 
significantly (p < 0.0001) during hydrocortisone administration to a peak on day 28. UPC ratios 183 
on day 28 and day 84 were significantly higher compared to day 1 and 2 (Fig. 1). Compared to 184 
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the control group UPC ratios in the I-HC group were significantly higher on day 28 and 56. Only 185 
two out of six dogs in the hydrocortisone group developed  clinically significant proteinuria 186 
defined as UPC ratio > 0.516, with maximal values in these two dogs of 1.78 and 1.63. One of 187 
these dogs (UPC ratio 1.78) showed pyuria with 8-12 leucocytes, results of urine cultures were 188 
negative in both these (and all the other dogs throughout the study), and urine electrophoresis 189 
showed a strong band in the molecular weight range of 65-70 kDa corresponding to albumin in 190 
both dogs. On d84 the dog with pyuria again showed an increased UPC ratio of 1.63, this time 191 
without pyuria, a negative urine culture and still a single band in the molecular weight range of 192 
65-70 kDa. 193 
In both groups there was a significant, but weak correlation between UPC ratios and SAP (r = 194 
0.611, p = 0.0001 in control dogs and r = 0.634, p = 0.0005 in the I-HC group). After 195 
hydrocortisone withdrawal UPC gradually decreased, reaching pre-treatment values within one 196 
month.  197 
Male dogs consistently had a higher UPC ratio than female dogs, except on d28, d56 and d84 198 
under hydrocortisone treatment, i.e. at times when urinary protein excretion was affected by 199 
hydrocortisone administration (Table 2). 200 
Microalbuminuria and urine albumin:creatinine ratio 201 
Before starting treatment all dogs in the I-HC group were found to be negative for MALB, 202 
whereas 2 male dogs in the control group were positive (++). During treatment 4 dogs in the I-203 
HC group developed variable degrees of MALB (+, ++, or +++) on days 28, 56 and 84, but not 204 
consistently. One month after stopping hydrocortisone administration MALB was no longer 205 
detectable in these 4 dogs. One dog that was negative for MALB during hydrocortisone 206 
administration was positive (++/+) on day 1 and 5 after hydrocortisone withdrawal. The two 207 
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dogs in the control group that were positive before the start of treatment remained positive, and 208 
all other control dogs remained negative throughout the study.  209 
UAC ratios before treatment were 0.017 (0.005 – 0.082) in the control group and 0.015 (0.009 – 210 
0.023) in the I-HC group. No change in UAC was seen in control dogs throughout the study 211 
(Table 2). UAC ratios gradually increased during hydrocortisone administration (Fig. 2) reaching 212 
a maximum on day 84, which showed a 13-fold (2.5 – 73.6) increase. UAC ratios were 213 
significantly higher on day 84 compared to baseline and day 1, and on day 56 compared to day 1. 214 
After stopping hydrocortisone administration UAC progressively decreased and returned to 215 
baseline values within 28 days. UAC ratios in the two control dogs which were positive in the 216 
MALB test throughout the study, ranged between 0.044 and 0.098 (median 0.067), and 0.048 217 
and 0.113 (median 0.081), respectively.  218 
Correlation between the microalbuminuria test and urine albumin:creatinine ratio 219 
There was a moderate and significant correlation between UAC and the MALB concentrations (r 220 
= 0.719, p < 0.0001). Overall 105 samples had a negative MALB result, 31 had a + result, four a 221 
++, and four a +++ result. UAC ratios in the different categories of MALB were 0.002-0.131 222 
(median 0.012) for negative, 0.044-0.242 (0.079) for low positive, 0.164-0.725 (0.325) for 223 
medium positive and 0.242-1.251 (1.023) for strong positive results. At a UAC cut-off of 0.078 224 
(mean+2SD in control dogs), sensitivity and specificity of the MALB were 81% and 88%, 225 
respectively. At a UAC cut-off of 0.03, sensitivity and specificity of the MALB were 64% and 226 
100%, respectively. 227 
Urine protein electrophoresis 228 
In the urine of the dogs two distinct bands were found by SDS-AGE, one in the molecular weight 229 
range of 65-70 kDa corresponding to albumin and the other in the range of 25-30 kDa. The 230 
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patterns in these dogs were characterized by either no band, an isolated band of 65-70 kDa, an 231 
isolated band of 25-30 kDa or both bands (Fig. 3A). Each dog of the I-HC group developed a 232 
band or showed a pronounced increase in the density of the band in the range of 65-70 kDa. 233 
After stopping hydrocortisone administration, the intensity of the albumin band decreased 234 
starting on day 5 and patterns were similar to baseline in each dog at d28p. A representative 235 
example of an SDS-AGE for one of these dogs is depicted in Fig. 3B. 236 
The band in the range of 25-30 kDa was only present in urine samples from male dogs. Each 237 
male dog showed this band during the study period, but not on every occasion. The sequence 238 
analysis of the tryptic peptides by LC-MSMS resulted in a sequence coverage of 6-16%. The 239 
partial sequences AVIRPGEDR (Fig. 4) and SHDLMLLHLEEPAK of canine arginine esterase 240 
were sequenced in all tested protein bands with a Mascot significance threshold of 0.05 241 
searching against the full Uniprot database. In some of the samples MSMS spectra matching the 242 
peptides SFIHPLYK and VMPHLMWIK were found. There was no additional significant 243 
Mascot hit for another protein in this band. 244 
 245 
DISCUSSION 246 
Hydrocortisone administration consistently increased BP in the dogs in this study. Whereas in 247 
humans a significant rise in SBP has been described within as little as 24 hours of commencing 248 
cortisol administration2,17 the rise in our dogs was not significant on days 1 and 5, but only on 249 
day 28. In contrast to dogs with spontaneous HC, where hypertension is a common finding and 250 
may be marked18, no dog in our study developed increased BP to the point of hypertension 251 
defined as SAP > 160 mmHg.19 As a matter of fact, the increase in SAP averaged only 20 mmHg 252 
(12-21 mmHg) within 1-2 months of hydrocortisone administration and thereafter even tended to 253 
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decrease during the treatment period. Recently, categorization of BP has been recommended due 254 
to risk of developing subsequent target organ damage. Applying this new classification scheme 255 
of hypertension, all dogs stayed in the lowest risk category (BP < 150/95 mmHg).20 256 
This discrepancy may have different causes. First, glucocorticoids may not be a relevant 257 
contributor to hypertension in spontaneous HC, second, the prevalence of hypertension in 258 
spontaneous HC may have been overestimated and third, our model may not closely resemble 259 
spontaneous HC. In dogs with spontaneous HC hormones other than cortisol may be responsible 260 
for the development of hypertension. Although in HC hypercortisolemia is considered to be of 261 
primary pathophysiological importance in dogs, excess production of aldosterone and precursors 262 
of the glucocorticoid and mineralocorticoid pathways, i.e. 17a-OH-pregnenolone, 17a-OH-263 
progesterone, 11-deoxycortisol, 21-deoxycortisol and corticosterone have been reported.10,21,22 264 
Of these, certainly aldosterone, but also various precursors may play a role in the development of 265 
hypertension.23,24 BP and the prevalence of hypertension may have been overestimated in clinical 266 
studies on HC. It has been shown that BP values strongly depend on acclimation to the 267 
measurement procedure25,26, with decreasing values over several days of measurements. 268 
Therefore, if BP measurements are obtained on a single day only, false high readings may result 269 
and hypertension may be overdiagnosed. A limitation of our model may be that our experimental 270 
dogs were only 3.5 years old, whereas spontaneous HC is typically a disease of middle-aged to 271 
older dogs. BP has been shown to increase with age27; thus, confounding factors related to age, 272 
e.g. atherosclerosis and obesity, may play a role in developing hypertension in spontaneous HC, 273 
whereas in our experimental healthy dogs excessive hydrocortisone was the only variable. Also, 274 
in spontaneous HC the cortisol excess may be more gradual but present for a much longer time. 275 
In this respect it is interesting to note, however, that blood pressure did not continue to increase 276 
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in the third month of hydrocortisone administration but tended, rather, to decrease, suggesting 277 
that there is no linear relationship between duration of HC and increasing blood pressure. 278 
Finally, with administration of hydrocortisone twice a day we created only two plasma peaks of 279 
cortisol, whereas in spontaneous HC there are multiple peaks throughout the day.28 280 
As indicated, not only was the increase in BP mild, but also SAP again started to decrease after 281 
d28. An explanation for this finding may be that chronic glucocorticoid treatment results in some 282 
metabolic adaptation. Glucocorticoid receptor downregulation in reaction to GC therapy was 283 
demonstrated in vitro and in vivo,29,30 but the possible mechanism of this receptor 284 
downregulation is poorly understood. There is evidence for an enhanced receptor degradation 285 
and a modulated GR expression.31,32 A recent study showed that in humans with endogenous HC 286 
not a GR downregulation but a diminished ligand affinity might partially protect the cells from 287 
the high cortisol levels.33 Another explanation for this finding may be that measurement on day 288 
56 and 84 fell into the months of July and August, i.e. the hottest months of the year. High 289 
temperatures result in vasodilatation, decreasing peripheral vascular resistance and reduction in 290 
BP.34 Also, extracellular volume due to water loss by panting and impaired urine concentrating 291 
ability may have been lower in dogs with HC. However, all dogs in the study had free access to 292 
water and a cool environment, and hematocrit was not different over time between groups, thus 293 
there was no reason to suspect hypovolemia.  294 
In all our experimental dogs BP returned to basal values shortly after cessation of hydrocortisone 295 
administration. In contrast, in dogs and humans with spontaneous HC hypertension often persists 296 
despite appropriate treatment and improvement of other clinical signs.4,35,36 This again indicates 297 
that hypertension in spontaneous HC is not just caused by the cortisol excess per se. The 298 
persistence of hypertension in spontaneous HC could be the result of irreversible peripheral 299 
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vascular remodeling followed by increased wall stiffness and increased vascular resistance. This 300 
hypothesis is supported by the finding that patients with a history of hypertension of less than 5 301 
years were more likely to become normotensive after adrenalectomy.37 However, the factors that 302 
influence persistence of hypertension have not been studied in either humans or dogs.  303 
In addition to an elevated BP we observed increased urinary protein excretion in hydrocortisone 304 
treated dogs. The increases in UPC ratios in most dogs were mild and smaller compared to dogs 305 
with spontaneous HC4 or dogs receiving prednisone for 42 days.8 The increase in proteinuria is 306 
thought to be primarily of glomerular origin, as there was only albuminuria as determined by 307 
SDS-AGE. Nevertheless, proteins other than albumin that may have been in the urine of our 308 
dogs were lost because the increase in UAC does not account for the increase in UPC, i.e. UPC 309 
was higher than UAC; thus, SDS-AGE was not sensitive enough to detect small amounts of 310 
multiple various proteins.  311 
Possible causes of increased glomerular proteinuria include increased intraglomerular pressure 312 
and damage to the glomerular basement membrane. Elevated BP and a significant albeit weak 313 
positive correlation between SAP and UPC in our dogs supports hypertension as being one 314 
causative mechanism of proteinuria. Even though systemic hypertension does not directly 315 
translate into increased intraglomerular pressure, glucocorticoids have also been shown to 316 
increase renal plasma flow and glomerular filtration rate in dogs.38,39,40 Thus, glucocorticoids 317 
may mediate proteinuria by hemodynamic alterations resulting in an increase in glomerular 318 
pressure. Altered renal histomorphology was found in dogs treated with prednisone for 42 days.8 319 
The most consistent finding was mild to moderate hypercellular glomerular tufts, suggestive of 320 
mesangial proliferation. Other findings were glomerular adhesions and moderately thickened 321 
Bowman’s capsules. Electron microscopy was characterized by occasional mild segmental 322 
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thickening of basement membranes, fusion of visceral cell foot processes and glomerular 323 
adhesions. Lack of pre-treatment renal histologic examination, lack of a control group and lack 324 
of follow-up histologic examination after discontinuation of glucocorticoids makes it difficult to 325 
say whether these changes are a result of glucocorticoid administration and whether histologic 326 
changes are reversible. As in our study no renal histologic examinations were performed, our 327 
results cannot answer the question of whether the quickly reversible proteinuria was due to either 328 
functional or morphological changes, or both. In spontaneous HC, proteinuria may or may not 329 
significantly decrease when the disease is well controlled.4,7,41 Presumably, elevated 330 
intraglomerular pressure in HC will lead to reversible or irreversible morphologic changes, 331 
depending on degree and chronicity.  332 
The 17% prevalence (2/12) of MALB in the healthy dogs in this study before any treatment is in 333 
accordance with other studies reporting a prevalence in healthy dogs ranging between 15 and 334 
19%.42,l It is important to note that there may be significant day-to-day variations of up to 30 -335 
80% in daily urinary albumin excretion in man.43 This variation is dependent on posture, 336 
exercise, and dietary factors, such as protein intake.44,45 Data from human patients indicate that 337 
MALB is associated with an increased cardiovascular risk in hypertensive patients46,47  and the 338 
nondiabetic population.48,49 In our two healthy dogs follow-up assays were positive throughout 339 
the study, and they are therefore thought to be microalbuminuric, however, the significance of 340 
this finding is unknown. The most important consideration when assessing MALB should 341 
probably be the context of where this result is obtained, i.e. is it any patient or a patient at risk of 342 
end organ damage. In this respect, the authors are unaware of any data that associate MALB with 343 
increased morbidity or mortality in dogs. 344 
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MALB can be quantitated by different means. Enzyme-linked immunoassay analysis, 345 
nephelometry and immunoturbidimetry are complicated, time consuming and expensive 346 
laboratory techniques, unsuitable for routine use. Recently, the ERD HealthScreen® test, a simple 347 
and fast test for the semiquantitative detection of MALB has been commercialized. In the present 348 
study, to verify the accuracy of MALB observed in healthy dogs and in dogs with iatrogenic HC 349 
as measured by this simple screening test we performed immunoturbidimetry as a quantitative 350 
reference method. In human medicine, an UAC ratio > 0.03 is considered abnormal and 351 
indicative of pathological MALB.13 Unfortunately few data exist on the normal range of UAC in 352 
healthy dogs, but in a previous study mean UAC ratio in 10 healthy dogs was 0.04±0.08m. The 353 
two healthy dogs with MALB were several times above the level of 0.078 and thus correctly 354 
identified with the screening test. Based on our findings the ERD HealthScreen® test appears to 355 
be an efficient and fast method for the semiquantititative detection of MALB in dogs with good 356 
correlation to a quantitative laboratory method.  357 
Higher UPC in male dogs when urinary protein excretion is not affected by hydrocortisone 358 
administration is explained by the distinct protein band in the molecular weight range of 25 to 30 359 
kDa, identified as arginine esterase. This enzyme, the major secretory protein of the prostatic 360 
gland, enters the bladder by reflux from the proximal urethra.50,51 An isolated band in the same 361 
molecular weight range has recently been described as free light chains and linked to male and 362 
female dogs exposed to or infected with certain infectious agents; i.e. Leishmania infantum, 363 
Ehrlichia canis and Babesia canis.52 On the basis of our results, this protein band  is a 364 
physiological finding in urine samples of intact male dogs, i.e. argininge esterase, and does not 365 
necessarily represent free light chains in every case.  366 
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In conclusion, our study showed that long-term hydrocortisone administration induces mild 367 
elevation of BP and mild proteinuria mainly characterized by albuminuria, suggesting proteinuria 368 
of glomerular origin. Both hypertension and proteinuria were reversible and completely restored 369 
within one month after cessation hydrocortisone administration. The higher UPC ratio in intact 370 
male dogs compared to female dogs can be explained by the physiological presence of arginine 371 
esterase.  372 
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a Hydrocortisone tablets, Hotz Pharmacy, Kusnacht, Switzerland 373 
b Synacthen®, Novartis Pharma Schweiz AG, Bern, Switzerland 374 
c Schellenberg S, Reusch CE, Glaus TM. Effect of adaptation on indirect blood pressure  375 
 measurement in conscious untrained beagle dogs. In: Congress Proceedings 15th ECVIM-CA  376 
 Congress, September 1-3, 2005, Glasgow, Scotland 377 
d SDI Vet/BP 6000; SDI, Waukesha, WI 378 
e Canine E.R.D.-HealthScreen® Test, Heska Corp, Fort Collins, CO 379 
f Microalbumin OSR6167 Olympus system reagent, Olympus Diagnostica GmbH, Clare, Ireland 380 
g Hydragel 5 Proteinurie, semiautomated Hydrasys, Sebia, Fulda, Germany 381 
h Promega 382 
i Thermo Finnigan 383 
j SPSS 11.0 for Windows, SPSS Inc., Chicago, IL,  384 
k GraphPad Prism 4, Graphpad Software Inc, San Diego, CA 385 
l Jensen WA, Grauer GF, Andrews J, et al. Prevalence of microalbuminuria in dogs. In:  386 
 Proceeding of the American College of Veterinary Internal Medicine annual meeting, May 23- 387 
 26, 2001, Denver, CO 388 
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LEGENDS 522 
Fig 1. Change in urine protein:creatinine ratios (UPC) in 12 dogs before, during and after 523 
administration of placebo (n = 6) or hydrocortisone (n = 6). An asterisk (*) indicates significant 524 
difference between the different time points. The grey background indicates the hydrocortisone 525 
or placebo treatment period. 526 
 527 
Fig 2. Change in urine albumin:creatinine ratios (UAC) in 12 dogs before, during and after 528 
administration of placebo (n = 6) or hydrocortisone (n = 6). An asterisk (*) indicates significant  529 
difference between the different time points. The grey background indicates the hydrocortisone  530 
or placebo treatment period. 531 
 532 
Fig 3. Analysis of urine protein patterns by agarose gel electrophoresis followed by staining with 533 
acid violet. The different protein patterns found in urine samples obtained from dogs in the 534 
control group (A). The change in urine protein pattern in a hydrocortisone treated female dog at 535 
the different time points (B). M, marker; m, male dog; f, female dog; Lxy, Lane xy 536 
 537 
Fig 4. Representative MSMS spectrum of the tryptic peptide AVIRPGEDR of canine ariginine 538 
esterase (ESTA_CANFA) identified by Mascot. The major fragments generated are labeled and 539 
the y- and b- fragments detected are indicated in the sequence. 540 
Controls I-HAC Controls I-HAC Controls I-HAC
Median (Range) Median (Range) Median (Range) Median (Range) Median (Range) Median (Range)
d0 128  (122 - 142) 123  (114 - 136) 63  (55 - 83) 69  (53 - 78) 90  (78 - 104) 90  (81 - 101)
d1 128  (123 - 135) 130  (118 - 136) 68  (63 - 75) 70  (66 - 78) 89  (82 - 95) 91  (84 - 99)
d5 126  (117 - 148) 133  (122 - 144) 66  (56 - 77) 75  (64 - 81) 89  (80 - 98) 94  (82 - 103)
d28 129  (116 - 149) 143  (128 - 148)a 70  (65 - 83) 81  (77 - 90)a 94  (83 - 107) 102  (95 - 109)a
d56 130  (122 - 145) 137  (134 - 139)a 72  (63 - 86) 82  (74 - 82)a 96  (84 - 105) 103  (96 - 105)a
d84 127  (119 - 144) 131  (129 - 141) 66  (59 - 81) 80  (71 - 81)a 89  (80 - 106) 98  (94 - 104)a
d1p 129  (118 - 141) 130  (124 - 144) 66  (54 - 75) 78  (65 - 84) 91  (80 - 103) 98  (89 - 103)
d5p 133  (117 - 152) 124  (106 - 136) 73  (53 - 86) 70  (55 - 76) 94  (77 - 115) 88  (77 - 98)
d28p 131  (123 - 145) 124  (117 - 128) 66  (60 - 86) 69  (61 - 81) 91  (86 - 105) 87  (84 - 97)
d56p 126  (118 - 140) 124  (116 - 130) 70  (59 - 81) 70  (61 - 82) 91  (85 - 104) 87  (79 - 101)
d84p 130  (121 - 143) 127  (117 - 133) 67  (60 - 79) 68  (62 - 77) 89  (79 - 107) 91  (85 - 95)
dx, day x of hydrocortisone treatment, dxp, day x after hydrocortisone treatment
a p < 0.05 versus d0
SAP (mmHg) DAP (mmHg) MAP (mmHg)
Table 1. Median values and ranges of systolic (SAP), diastolic (DAP) and mean arterial blood pressure (MAP) in control 
and hydrocortisone treated dogs at the different time points.
control dogs I-HC dogs P value control dogs I-HC dogs P value
Median (Range) Median (Range) Median (Range) Median (Range)
d0 0.21 (0.13 - 0.38) 0.17 (0.15 - 0.28) 0.937 0.017 (0.005 - 0.082)   0.015 (0.009 - 0.023) 0.937
d1 0.15 (0.12 - 0.32) 0.12 (0.09 - 0.22) 0.240 0.014 (0.006 - 0.060)   0.013 (0.010 - 0.028) 0.818
d5 0.18 (0.10 - 0.23) 0.15 (0.08 - 0.28) 0.937 0.013 (0.004 - 0.048)   0.016 (0.005 - 0.043) 1.000
d28 0.19 (0.13 - 0.29) 0.38 (0.18 - 1.78)a 0.026 0.024 (0.004 - 0.067)   0.045 (0.012 - 0.795) 0.240
d56 0.19 (0.11 - 0.30) 0.30 (0.20 - 0.51) 0.041 0.016 (0.005 - 0.079)   0.083 (0.021 - 0.339)b 0.015
d84 0.22 (0.10 - 0.36) 0.33 (0.21 - 1.63)a 0.065 0.020 (0.003 - 0.103)   0.133 (0.034 - 1.251)b,c 0.026
d1p 0.24 (0.09 - 0.34) 0.34 (0.20 - 1.03) 0.180 0.023 (0.003 - 0.070)   0.101 (0.011 - 0.725) 0.041
d5p 0.24 (0.12 - 0.30) 0.24 (0.19 - 0.67) 0.699 0.035 (0.002 - 0.078)   0.037 (0.016 - 0.311) 0.589
d28p 0.20 (0.08 - 0.36) 0.17 (0.11 - 0.31) 0.937 0.020 (0.002 - 0.093)   0.010 (0.005 - 0.032) 1.000
d56p 0.18 (0.09 - 0.36) 0.18 (0.14 - 0.22) 0.937 0.018 (0.004 - 0.113)   0.013 (0.003 - 0.025) 0.699
d84p 0.25 (0.10 - 0.35) 0.20 (0.13 - 0.30) 0.699 0.027 (0.007 - 0.104)   0.014 (0.005 - 0.037) 0.485
dx, day x of hydrocortisone treatment, dxp, day x after hydrocortisone treatment
a p < 0.05 versus d1 and d5, b p < 0.05 versus d1, c p < 0.05 versus d0
UPC UAC
Table 2. Median values, ranges and P-values (control vs. I-HC dogs) of urine protein:creatinine (UPC) and urine 
albumin:creatinine (UAC) ratios in control dogs and dogs of the I-HC group at the different time points.
male dogs female dogs P value
Median (Range) Median (Range)
d0 0.28  (0.18 - 0.38) 0.15  (0.13 - 0.16) 0.002
d1 0.19  (0.11 - 0.32) 0.13  (0.09 - 0.15) 0.041
d5 0.22  (0.16 - 0.28) 0.12  (0.08 - 0.14) 0.002
d28 0.30  (0.23 - 1.78) 0.17  (0.13 - 1.63) 0.065
d56 0.28  (0.20 - 0.49) 0.20  (0.11 - 0.51) 0.394
d84 0.33  (0.21 - 1.63) 0.24  (0.10 - 0.34) 0.180
d1p 0.34  (0.20 - 1.03) 0.20  (0.09 - 0.39) 0.065
d5p 0.29  (0.19 - 0.67) 0.19  (0.12 - 0.28) 0.026
d28p 0.30  (0.12 - 0.36) 0.11  (0.08 - 0.17) 0.009
d56p 0.22  (0.16 - 0.36) 0.14  (0.09 - 0.19) 0.004
d84p 0.29  (0.21 - 0.35) 0.14  (0.10 - 0.21) 0.002
UPC
Table 3. Median values, ranges and P-values (male vs female dogs) of 
urine protein:creatinine ratios (UPC) in all male and female dogs at the 
different time points.
dx, day x of hydrocortisone treatment, dxp, day x after hydrocortisone 
treatment
 Fig 1. Change in urine protein:creatinine ratios (UPC) in 12 dogs before, during and after administration of placebo (n = 6) or 
hydrocortisone (n = 6). An asterisk (*) indicates significant difference between the different time points. The grey background indicates 
the hydrocortisone or placebo treatment period. 
 
 Fig 2. Change in urine albumin:creatinine ratios (UAC) in 12 dogs before, during and after administration of placebo (n = 6) or 
hydrocortisone (n = 6). An asterisk (*) indicates significant difference between the different time points. The grey background indicates 
the hydrocortisone or placebo treatment period. 
 
 Fig 3. Analysis of urine protein patterns by agarose gel electrophoresis followed by staining with acid violet. The different protein 
patterns found in urine samples obtained from dogs in the control group (A). The change in urine protein pattern in a hydrocortisone 
treated female dog at the different time points (B). M, marker; m, male dog; f, female dog. 
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